Benzetacil 1,200,000 IU powder and solvent for injectable suspension

Patient Information Leaflet

Introduction

Patient Information Leaflet

BENZETACIL 1,200,000 IU powder and solvent for injectable suspension

Benzathine benzylpenicillin

Read the entire leaflet carefully before you start using the medicine, as it contains important information for you. Keep this leaflet, as you may need to read it again. If you have any questions, consult your doctor or pharmacist. This medicine has been prescribed for you; do not give it to others, even if they have the same symptoms, as it may harm them. If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Package leaflet contents:

1. What BENZETACIL 1,200,000 IU is and what it is used for
2. What you need to know before using BENZETACIL 1,200,000 IU
3. How to use BENZETACIL 1,200,000 IU
4. Possible side effects
5. How to store BENZETACIL 1,200,000 IU
6. Contents of the pack and other information

1. What BENZETACIL 1,200,000 IU is and what it is used for

BENZETACIL 1,200,000 IU contains benzathine benzylpenicillin, an antibiotic belonging to the penicillin family.

Antibiotics are used to treat bacterial infections and are not effective against viral infections such as influenza or the common cold. It is important to follow your doctor's instructions regarding dosage, dosing interval, and duration of treatment. Do not keep or reuse this medicine. If you have any antibiotic left after completing the treatment, return it to the pharmacy for proper disposal. Do not dispose of medicines down the drain or in the household waste.

Benzathine benzylpenicillin is indicated for the treatment of infections caused by susceptible organisms, such as:

• Pharyngitis and tonsillitis.
• Syphilis: primary and secondary.
• Latent syphilis (except neurosyphilis).
• Erysipelas (skin infection).
• Tropical infectious skin diseases caused by bacteria of the Treponema species, such as yaws or pinta.

Benzathine benzylpenicillin is also indicated for the prevention of the following diseases:

• Rheumatic fever.
• Post-streptococcal glomerulonephritis (a specific form of kidney inflammation).
• Erysipelas.

2. What you need to know before using BENZETACIL 1,200,000 IU

Do not use BENZETACIL 1,200,000 IU

If you are allergic to the active substance or to any of the other components of this medicine (listed in section 6).

If you are allergic (hypersensitive) to penicillins, cephalosporins, or soy.

If you have ever had an allergic reaction while taking an antibiotic or other medicines. This may include a skin rash or swelling of the face or neck.

Warnings and precautions

Talk to your doctor or pharmacist before using BENZETACIL 1,200,000 IU:

• if you have ever had an allergic reaction to other antibiotics such as penicillin or other beta-lactam antibiotics,
• if you have kidney problems (your doctor may need to adjust the dose of this medicine),
• if you have liver problems,
• if you are on a low-sodium diet.

BENZETACIL 1,200,000 IU should not be used in tissues with poor blood flow.

If you experience allergic symptoms (e.g., skin rash, itching, shortness of breath), consult your doctor immediately.

A hypersensitivity test should be performed, if possible, prior to treatment. If an allergic reaction occurs, your doctor will discontinue treatment and, if necessary, initiate appropriate therapy.

If you are allergic to cephalosporins. In patients hypersensitive to cephalosporins, cross-allergic reactions should be considered possible.

If you have asthma or are allergic to hay fever, inform your doctor. Severe immediate allergic reactions may occur when treatment is administered for the first time. In some cases, you may be kept under observation for at least 30 minutes after administration of the medicine in case of an acute allergic reaction. If you are allergic, your doctor will take appropriate measures. Treatment with BENZETACIL 1,200,000 IU must be stopped immediately.

When treating syphilis, a reaction of the body to bacterial toxins may occur, which can last for several days (Jarisch-Herxheimer reaction, see section 4). Symptoms include sudden fever (sometimes with chills), pallor, followed by skin flushing, headache, muscle and joint pain, or fatigue. Your doctor will initiate appropriate treatment to suppress or alleviate a Jarisch-Herxheimer reaction.

If you have renal and/or severe hepatic impairment, the dose should be adjusted. For long-term treatment (more than 5 days), your doctor may schedule blood count monitoring and tests to evaluate kidney function.

Like other antibiotics, treatment with BENZETACIL 1,200,000 IU may lead to the overgrowth of non-sensitive microorganisms. Contact your doctor if you develop a fungal infection.

If you have ulcerative colitis, Crohn's disease, or pseudomembranous colitis (persistent and/or severe diarrhea during or after administration of this medicine), you should be under strict clinical monitoring with periodic laboratory tests.

During treatment with antibiotics, including BENZETACIL 1,200,000 IU, diarrhea may occur even several weeks after treatment has ended. If you experience severe or persistent diarrhea, or notice blood or mucus in your stools, inform your doctor immediately so that treatment can be stopped. Do not take medications intended to inhibit or delay intestinal transit.

Other medicines and BENZETACIL 1,200,000 IU

Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

Consult your doctor if you are taking any of the following medicines:

• Allopurinol and Probenecid (medicines for gout or gouty arthritis)
• Methotrexate (a medicine used in chemotherapy)
• Other antibiotics
• Anticoagulants (medicines to thin the blood)

Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

Use of BENZETACIL 1,200,000 IU with food and drink

Treatment with BENZETACIL is not affected when administered with food.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine.

BENZETACIL 1,200,000 IU should not be used during pregnancy unless the woman's clinical condition requires treatment with benzathine benzylpenicillin.

Small amounts of benzylpenicillin pass into breast milk. Although no adverse effects have been reported in infants so far, the possibility of sensitization or interference with intestinal flora should be considered. If diarrhea, candidiasis, or skin rash occurs in the infant, consult your doctor immediately. Breastfeeding may be resumed 24 hours after the end of treatment.

Driving and using machines

There is no evidence of effects on the ability to drive or operate machinery.

BENZETACIL 1,200,000 IU contains Sodium

This medicine contains less than 1 mmol of sodium (23 mg) per vial; this is essentially “sodium-free”.

BENZETACIL 1,200,000 IU contains Soy Lecithin

This medicine contains 10.25 mg of soy lecithin per vial. It should not be used if you are allergic to peanuts or soy.

3. How to use BENZETACIL 1,200,000 IU

Follow exactly the administration instructions given by your doctor for this medicine.

If in doubt, consult your doctor or pharmacist again.

In general, BENZETACIL 1,200,000 IU is administered by a healthcare professional.

The recommended dose is:

General treatment:

Adults and adolescents: 1,200,000 IU once weekly.

Children weighing > 30 kg: 1,200,000 IU once weekly.

Children weighing < 30 kg: 600,000 IU once weekly.

Duration of treatment: a single dose.

Treatment of Syphilis:

• Primary and secondary syphilis:

Adults and adolescents: 2,400,000 IU administered as a single dose.

Children: 50,000 IU/kg body weight, not exceeding 2,400,000 IU.

If clinical symptoms recur or laboratory results remain positive, treatment should be repeated.

Duration of treatment: a single dose.

• Latent syphilis:

Adults and adolescents: 2,400,000 IU once weekly.

Children: 50,000 IU/kg body weight, not exceeding 2,400,000 IU.

Duration of treatment: 3 weeks.

• Congenital syphilis: without neurological involvement

• Newborns and infants: 1 x 50,000 IU/kg body weight

Duration of treatment: a single dose.

Treatment of tropical infectious skin diseases (yaws, pinta):

Adults and adolescents: 1,200,000 IU as a single dose.

Children weighing > 30 kg: 1,200,000 IU as a single dose.

Children weighing < 30 kg: 600,000 IU as a single dose.

Duration of treatment: a single dose.

Prophylaxis of rheumatic fever, post-streptococcal glomerulonephritis, and erysipelas:

Adults and adolescents: 1,200,000 IU every 3–4 weeks.

Children weighing > 30 kg: 1,200,000 IU every 3–4 weeks.

Children weighing < 30 kg: 600,000 IU every 3–4 weeks.

Duration of treatment:

1. Without cardiac involvement: at least 5 years, or until 21 years of age.
2. Temporary heart involvement: at least 10 years, or until 21 years of age.
3. Persistent cardiac involvement: at least 10 years or until 40 years of age; sometimes lifelong treatment is required.

Patients with renal and/or hepatic impairment

The dose and dosing interval will be determined by your doctor. Depending on the degree of kidney and/or liver function, your doctor may consider adjusting the dose.

Method of administration

BENZETACIL 1,200,000 IU is administered exclusively by deep intramuscular injection.

The injection must not be administered into tissues with poor blood supply.

In case of repeated intramuscular injections, the injection site should be rotated.

Severe local reactions may occur during intramuscular administration, especially in young children. For this reason, alternative treatments, such as a different penicillin formulation, may be considered whenever possible.

For instructions on reconstitution of the medicine prior to administration, see the section “Preparation instructions” at the end of this leaflet.

If you use more BENZETACIL 1,200,000 IU than you should

At extremely high doses, penicillins may cause neuromuscular excitability or epileptiform seizures.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately, or call the Toxicology Information Service at telephone 91 562 04 20, indicating the medicine and amount used.

If you forget to use BENZETACIL 1,200,000 IU

Do not use a double dose to make up for forgotten doses. Use the missed dose as soon as possible, then continue with your regular schedule.

If you stop treatment with BENZETACIL 1,200,000 IU

If you have any further questions about the use of this product, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

The adverse effects of this medicine are generally transient and mild. In most cases, adverse effects are of allergic origin and manifest dermatologically. The toxicological profile of this drug is similar to that of other penicillins, although allergic manifestations are somewhat more frequent, especially with parenteral administration.

Severe allergic reactions (anaphylactic reactions or angioedema) may occur, such as:

• skin rash or itching
• difficulty breathing or chest tightness
• swelling of the eyelids, face, or lips
• swelling or redness of the tongue
• fever
• joint pain
• swollen lymph nodes

In case of an allergic reaction, administration should be discontinued and treatment initiated with antihistamines (antiallergic agents) and/or corticosteroids (anti-inflammatory agents).

The adverse effects listed below are classified according to their frequency and by organ system. Frequency categories are defined by the following convention:

Very common (affects more than 1 in 10 people);
Common (affects up to 1 in 100 people);
Uncommon (affects up to 1 in 1,000 people);
Rare (affects between 1 and 10 in 10,000 people);
Very rare (affects less than 1 in 10,000 people);
Frequency not known (cannot be estimated from available data).

Infections and infestations:

Common: fungal infection (candidiasis).

Blood and lymphatic system disorders:

Very rare: blood cell abnormalities (eosinophilia, neutropenia, leucopenia, agranulocytosis, granulocytopenia, pancytopenia) and coagulation disorders.

Frequency not known: Prolongation of bleeding time and prothrombin time. Haemolytic anaemia (reduced levels of red blood cells in blood), thrombocytopenia (reduced levels of platelets in blood).

Gastrointestinal disorders:

Common: Nausea.

Uncommon: inflammation of the oral mucosa (stomatitis) and inflammation of the tongue (glossitis), vomiting.

Rare: pseudomembranous colitis (inflammation of the colon), diarrhoea.

Immune system disorders:

Rare: allergic reactions: skin rash similar to that caused by a nettle (urticaria), angioedema (swelling), skin reactions (erythema multiforme, exfoliative dermatitis), fever, painful joints, anaphylactic shock with collapse, and anaphylactoid reactions (asthma, haemorrhagic skin lesions known as purpura, gastrointestinal discomfort).

Frequency not known: serum sickness. When treating syphilis, a reaction known as the Jarisch-Herxheimer reaction may occur due to the destruction of bacteria, characterized by fever, chills, and general and focal symptoms. Para-allergic reactions may occur in patients with cutaneous mycosis (skin fungus). Angioedema (swelling of the skin, mucosa, and subcutaneous tissue, usually localized in the face, mouth, or tongue).

Nervous system disorders:

Rare: neuropathy (nerve damage).

Frequency not known:
Encephalopathy with insomnia, confusion, hallucinations, seizures, and epileptic state; myoclonus (muscle contractions); and, more rarely, aseptic meningitis and benign intracranial hypertension. Metabolic encephalopathy (neurological disorders with seizures and loss of consciousness).

Hepatic disorders:

Frequency not known: inflammation of the liver (hepatitis), bile flow disorder (cholestasis).

Skin and subcutaneous tissue disorders:

Common: rashes, exanthems (reddish skin eruptions), pruritus (itching).

Frequency not known: AGEP - Acute Generalized Exanthematous Pustulosis with symptoms such as severe drug-related skin reactions with or without skin redness, fever, pustules, maculopapular eruption (flat, red areas on the skin), morbilliform eruption (rash resembling measles), itching, erythema (inflammatory redness of the skin).

Renal and urinary disorders:

Rare: kidney disease (nephropathy), kidney inflammation (interstitial nephritis), albuminuria, cylindruria (excretion of proteins in urine), and haematuria (blood in urine). Oliguria (reduced urine production) and anuria (absence of urine excretion) may occur at high doses and usually resolve within 48 hours after stopping treatment.

General disorders and administration site conditions:

Common: pain and/or infiltrates at the injection site.

Investigations:

Common: changes in certain laboratory tests and investigations such as:

• Positive direct Coombs test.

-- False positives in urine protein determination using precipitation techniques (Folin-Ciocalteu-Lowry and biuret methods)

• False positives in amino acid determination tests.
• Interference with albumin measurement by electrophoretic methods, simulating hyperalbuminemia.
• Non-enzymatic tests may yield false positive results for glucose in urine and urobilinogen.
• Elevated levels when measuring urinary keto steroids (Zimmermann reaction)

Reporting suspected adverse reactions:

It is important to report suspected adverse reactions to the medicine after its authorization. This enables continued monitoring of the benefit-risk balance of the medicine. Healthcare professionals are encouraged to report suspected adverse reactions via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es.

5. Storage of BENZETACIL 1,200,000 IU

Keep this medicine out of sight and reach of children.

The injectable suspension powder (vial) must be stored in a dry place.

Reconstituted vial: The reconstituted product should be used immediately for intramuscular administration.

Do not use this medicine after the expiry date stated on the packaging after "EXP". The expiry date refers to the last day of the month indicated.

Medicines must not be disposed of via wastewater or household waste. Unused medicines and their containers should be returned to the Sigre Point at your pharmacy. If you have any doubts, ask your pharmacist how to dispose of medicines and containers you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of BENZETACIL 1.200.000 IU

Vial:

• The active substance is Benzathine benzylpenicillin (benzylpenicillin G benzathine). Each vial contains 1,200,000 IU of Benzathine benzylpenicillin.
• The other components (excipients) are: Tween 80, lecithin, sodium citrate (E-331).

Ampoule: Water for injections

After reconstitution of the vial with 4 ml of water, the final volume is 4.8 ml, containing 1,200,000 IU of Benzathine benzylpenicillin.

There are 300,000 IU of benzathine benzylpenicillin in 1.2 ml of suspension.

Appearance of the medicine and contents of the pack

BENZETACIL 1.200.000 IU is supplied in single packs: 1 vial and 1 ampoule, and in clinical packs: 100 vials and 100 ampoules.

Marketing Authorization Holder and Manufacturer:

Marketing Authorization Holder:

Laboratorio Reig Jofré, S.A.

Gran Capitán, 10

08970 San Joan Despí (Barcelona)

Manufacturer:

Laboratorio Reig Jofré, S.A.

Jarama, 111 - Polígono Industrial

45007 Toledo

Date of the most recent review of this leaflet: October 2021.

Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS) http://www.aemps.es/

---

This information is intended for healthcare professionals only:

Medicine: BENZETACIL 1.200.000 IU powder and solvent for injectable suspension

Method of administration:

BENZETACIL 1.200.000 IU is administered exclusively by deep intramuscular injection into the upper outer quadrant of the gluteus or into the ventro-gluteal site according to the Hochstetter method, with the needle directed toward the iliac crest or as per the Hochstetter technique. The puncture should be as perpendicular as possible to the skin surface, and the injection should be given as far away as possible from major blood vessels. For repeated doses, change the injection site.

In children, the recommended injection site is the mid-lateral thigh muscle (femoral quadriceps). Injection into the deltoid muscle is only recommended if the muscle mass is adequate. In this case, care must be taken to avoid the radial nerve.

In infants and young children, the peripheral area of the upper outer quadrant of the gluteal region should only be used as an injection site in exceptional cases, to avoid injury to the sciatic nerve.

Before injection, intravascular administration must be ruled out by aspiration. For repeated doses, change the injection site.

For depot preparations, although it is recommended not to administer more than 5 ml per injection site as a tolerance limit, the entire content of the vial may be administered at a single site. In case of excessive pain, the volume may be divided between two injection sites.

The injection should be administered as slowly as possible and only with low pressure.

Avoid pressing and/or rubbing the injection site after administration.

Preparation instructions:

For injection of BENZETACIL, use a long needle with a gauge of 0.9 mm. Aseptically prepare the suspension by injecting the 4 ml of water for injections from the ampoule provided in the pack into the vial.

Shake until a homogeneous suspension is obtained. Aspirate the contents of the vial into a syringe.

1.2 ml of reconstituted injectable suspension of BENZETACIL 1.200.000 IU contains 300,000 IU of benzathine benzylpenicillin.

To inject, insert the needle deeply into the gluteal muscle, attach the syringe, and aspirate by pulling back the plunger to ensure no blood appears, confirming that the needle is not within the lumen of a blood vessel. Administer the injection as soon as possible to prevent crystallization within the needle, which may cause increased pain for the patient.

For single use only. Discard any unused suspension.